Does ponatinib cross the blood–brain barrier?

British Journal of Haematology

Volumn 179, Issue 3, 2017, Pages 497-498

  Abid, Muhammad B ^a   De Mel, Sanjay ^a  

^a Cancer Science Institute of Singapore   (Singapore)

Author keywords

Ph+ALL; ponatinib; T315I mutation; tyrosine kinase inhibitor

Indexed keywords

BCR ABL1 PROTEIN; DASATINIB; MERCAPTOPURINE; METHOTREXATE; PONATINIB; PREDNISONE; PROTEIN; STEROID; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; COGNITIVE DEFECT; CYTOGENETICS; FALLING; FLOW CYTOMETRY; HUMAN; KARYOTYPING; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; REMISSION; GENETICS; METABOLISM; MUTATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; MALE; MUTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIDAZINES; TREATMENT OUTCOME;

EID: 84977111001     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14222     Document Type: Letter

References (6)

1. Cortes, J.E., Kim, D.W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F.E., Apperley, J.F., Khoury, H.J., Talpaz, M., DiPersio, J., DeAngelo, D.J., Abruzzese, E., Rea, D., Baccarani, M., Müller, M.C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Guilhot, F., Deininger, M.W., Hochhaus, A., Hughes, T., Goldman, J.M., Shah, N.P. & Kantarjian, H. (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 369, 1783–1796.
2. Foà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M.S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., Nobile, F., Ferrara, F., Castagnola, C., Sica, S., Leoni, P., Zuffa, E., Fozza, C., Luppi, M., Candoni, A., Iacobucci, I., Soverini, S., Mandelli, F., Martinelli, G. & Baccarani, M.; GIMEMA Acute Leukemia Working Party. (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 118, 6521–6528.
3. Gaur, S., Torabi, A.R. & Corral, J. (2014) Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor. In Vivo, 28, 1149–1153.
4. Jabbour, E., Thomas, D., Cortes, J., Kantarjian, H.M. & O'Brien, S. (2010) Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer, 116, 2290–2300.
5. Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., Eccersley, L., Hjorth-Hansen, H., Höglund, M., Klamova, H., Knutsen, H., Parikh, S., Raffoux, E., Gruber, F., Brito-Babapulle, F., Dombret, H., Duarte, R.F., Elonen, E., Paquette, R., Zwaan, C.M. & Lee, F.Y. (2008) Dasatinib crosses the blood–brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112, 1005–1112.
6. Wolff, N.C., Richardson, J.A., Egorin, M. & Ilaria, Jr, R.L. (2003) The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood, 101, 5010–5013.